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Abstract
Purpose of Review Muscular dystrophies are a group of severe
degenerative disorders characterized by muscle fiber degenera-
tion and death. Therapies designed to restoremuscle homeostasis
and to replace dying fibers are being experimented, but none of
those in clinical trials are suitable to permanently address indi-
vidual gene mutation. The purpose of this review is to discuss
genome editing tools such as CRISPR/Cas (clustered regularly
interspaced short palindromic repeats/CRISPR-associated),
which enable direct sequence alteration and could potentially
be adopted to correct the genetic defect leading to muscle
impairment.
Recent Findings Recent findings show that advances in gene
therapy, when combined with traditional viral vector-based
approaches, are bringing the field of regenerative medicine
closer to precision-based medicine.
Summary The use of such programmable nucleases is proving
beneficial for the creation of more accurate in vitro and in vivo
disease models. Several gene and cell-therapy studies have
been performed on satellite cells, the primary skeletal muscle
stem cells involved in muscle regeneration. However, these
have mainly been based on artificial replacement or augmen-
tation of the missing protein. Satellite cells are a particularly
appealing target to address these innovative technologies for
the treatment of muscular dystrophies.
Keywords Stemcells .Musculardystrophies .CRISPR/Cas .
Genome editing . Gene therapy . Precisionmedicine
Introduction
Among the many tissues that take part in the formation of the
human body, skeletal muscle contributes to almost 50% of our
body mass. Skeletal muscle formation, or myogenesis, is an
active process that begins in embryonic development. Muscle
growth and regeneration can occur throughout the entire
lifespan to ensure its fundamental role in structural support
and posture maintenance, breathing, thermoregulation, and
metabolism.
The functional unit of skeletal muscle is the myofibre. This
is an elongated and multinucleated cell derived from the fu-
sion of undifferentiated muscle precursors, known as myo-
blasts. During myogenesis, skeletal muscle stem cells (satel-
lite cells) are generated (Fig. 1 a). Satellite cells are located
underneath the basal lamina of the muscle fiber and contribute
to muscle growth, maintenance, and regeneration. Satellite
cells are normally quiescent in adult muscle until a stimulus
or damage that can arise from either physiological conditions
(exercise [1], aging [2]) or diseases (cachexia [3], sarcopenia
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[4], muscular dystrophies [5]) activates them to trigger muscle
regeneration.
Upon activation, satellite cells generate myogenic cells
called myoblasts, that either fuse together to form myotubes
that mature into newmyofibers or repair damaged segments of
existing myofibres [6].
Muscular dystrophies are genetically inherited pathologies
characterized by extensive muscle fiber damage that leads to
the activation of satellite cells and to the exhaustion of their
pool, with consequent impairment of the regenerative process.
There are, at present, no therapies available to address muscle
degeneration.
Fig. 1 a Satellite cells originate from dorsal somites and are
characterized by the expression of intracellular and extracellular
markers: Pax7, CXCR4, Syndecan 3- and -4, c-Met, VCAM1,
NCAM1, Caveolin-1, CD34, Calcitonin receptor, M-Cadherin. Integrin-
α7 (ITGA7) and integrin-β1 (ITGB1). Satellite cells generate both cells
aimed to replenish the satellite cell pool and cells that develop into myo-
blasts, precursors of the muscle fiber. Satellite cells reside at the periphery
of the muscle fiber. b Diagram of regenerative medicine: satellite cells
isolated from patient muscle and satellite-cells derived myoblasts can be
treated with engineered nucleases (TALEN/CRISPR) to introduce a dou-
ble strand break in their genome sequence, thus eliminating the mutation.
NHEJ or HDR re-join the cleaved DS break, restoring the sequence.
Corrected cells are then transplanted back into patient’s muscle
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Regenerative medicine aims to combine gene- and cell-
therapy approaches to restore the genetic defects in diseased
cells, tissues, and organs in order to re-establish their function-
ality. In muscle, regeneration can be implemented by isolating
patient-derived cells, correcting and transplanting them back
into the damaged tissue. However, none of the gene therapy
approaches designed to date can be expanded to correct the
heterogeneous variety of mutations responsible for each mus-
cular dystrophy subtype, limiting their applicability to a subset
of patients only.
Satellite Cells: Origin and Characterization
The ability of muscle fibers to repair damage and regenerate
comes from the presence of stem cell populations that coop-
erate in the myogenic process. Among them, satellite cells
have proven to be essential and indispensable in the regener-
ation of muscle [7–10]. This stem cell population was first
discovered in 1961 by Alexander Mauro and Robert Katz
[11, 12] who, in two independent studies, identified cells lo-
cated between the plasma membrane and the basement mem-
brane of skeletal muscle fibers isolated from frogs and rats.
Harunori Ishikawa later observed that this defined peripheral
location is conserved in most mammalian species and named
them satellite cells [13]. Muscle satellite cells have distinct
origins that correlate to the particular muscle they will gener-
ate; apart from head muscles, most of the skeletal muscles
originate from the dorsal aspect of the somites in a process
tightly controlled by the expression of muscle-specific tran-
scription factors that vary dynamically according to specific
cell-cycle phases [14]. Embryonically, dermomyotome cells,
committed tomyogenic development, express the intracellular
markers Paired-box domain transcription factors Pax3 and
Pax7, which are crucial regulators of trunk and limb muscle
formation [15] as they act upstream of hierarchically related
muscle regulatory factors (MRFs). Specifically, Pax3 expres-
sion appears to be indispensable during early embryonic de-
velopment, but is less expressed in adult muscle [16]. Pax7
instead, takes the lead in later gestational stages and in post-
natal muscle growth [17], and as it is expressed both in quies-
cent and activated satellite cells, it is considered to be a uni-
versal marker [18]. Cells expressing high levels of Pax7 are
characterized by lower metabolic rate and lower division rate,
while a low level of Pax7 correlates with higher myogenin
levels [19].
Other than their expression of Pax7 and location at the
periphery of the fiber, satellite cells are defined by a high ratio
of nucleus-to-cytoplasm and cell surface markers: M-
cadherin, α7- and β1- integrins, tyrosine receptor kinase c-
Met (regulated by Pax3), CXCR4 (C-X-C chemokine receptor
type 4), syndecan-3 and-4, calcitonin receptor, caveolin-1,
CD34, VCAM1 (vascular cell adhesion molecule-1) and
NCAM1 (neural cell adhesion molecule-1) [20, 21] Barx2 as
well as nuclear envelope proteins laminA/C and Emerin [21,
22]. Since these markers can also be present in other cells,
selection of a combination of specific markers can be used
to isolate pure satellite cell pools via fluorescence-activated
cell sorting (FACS): these are defined through positive selec-
tion of cells expressing both α7-integrin and CD34, combined
with negative selection of CD45 (marker of hemotopoietic
lineage), CD11b (leukocytes), CD31 (leukocytes and endo-
thelial cells), and Sca-1 (mesenchymal and hematopoietic
stem cells) [23]. Alternatively, satellite cells can be isolated
by physically stripping them from myofibres [24, 25].
A broad range of heterogeneity exists within the satellite
stem cell population. There is evidence that there are two
subpopulations of satellite cells that are functionally distinct;
one is responsible for muscle growth, is present in higher
amount in males and decreases with aging, while the other,
whose task is muscle regeneration after injury, is not sex-
related and is maintained with age [26]. Satellite cells differ
in fast and slowmuscles, as those residing in fast muscles tend
to form fast myosin isoforms, compared to those residing in
slow muscles that form slow myosin isoforms [27].
Also, satellite cells undergo asymmetric divisions fromwhich
arise both cells committed to myogenic differentiation
(myoblasts) and cells destined to replenish the quiescent satellite
cell pool [28]: a subpopulation of cells, characterized by differ-
ential markers and Myf5 regulatory factor expression, showed a
reduced division rate and higher engraftment capacity in amouse
model and is thought to be responsible for themaintenance of the
satellite cell pool, as opposed to the remaining population which
is more prone to differentiation [10].
In vitro and in vivo studies have also highlighted differ-
ences in satellite cells derived from muscles having different
embryonic origin. For example, Pax3 is highly expressed in
the diaphragm and trunk muscles together with Pax7, but is
not expressed in the hindlimbs [29]. Diaphragm satellite cells
exhibit greater replicative potential compared to limb, trunk,
and facial muscle, though are limited in their ability to differ-
entiate [30]. A chronic proliferation is also observed in laryn-
geal, pharyngeal, and extraocular satellite cells, possibly due
to a subpopulation of highly active satellite cells [31–33].
Delayed differentiation seems to correlate with impaired re-
generative ability in masseter muscles following acute inju-
ries, despite the increase in number of satellite cells present in
this muscle with age [34]. However, the method with which
different satellite cell profiles contribute to the specific in-
volvement of preferential muscles in distinct pathologies is
still matter of debate in the scientific community.
Muscle Regeneration
Normally, satellite cells in adult muscles lie in their niche in a
quiescent state until a stimulus Bawakens^ the dormant cells
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and stimulates them to proliferate and differentiate into mature
myofibers.
Upon stress or damage, the niche and fibro/adipogenic pre-
cursors [35] in the fiber provide stimuli to promote muscle re-
generation. The muscle fiber releases molecules, responsible for
the inflammatory response, that recruit neutrophils and macro-
phages that remove the cellular debris, while leaving the basal
lamina intact as a scaffold for muscle regeneration [36, 37].
Fibro-adipogenic precursors and connective tissue-fibroblasts
[9] are also involved in the regenerative process, as they release
pro-differentiation signals that help muscle healing [35].
Meanwhile, the fiber rapidly produces growth factors,
chemokines, and cytokines and releases themboth systematically
and locally to activate satellite cells and stimulate them to prolif-
erate and undergo asymmetric divisions [38–40].
The regenerative process largely recapitulates muscle fiber
development, as both are characterized by differential expres-
sion of four essential myogenic regulatory factors (MRFs),
hierarchically expressed:Myf5, MyoD,MRF4, and myogenin
[41]. In early myogenesis, Myf5 is the first to be expressed
followed by MyoD. Their combined expression plays a criti-
cal role in muscle formation, as shown in double Myf5-and-
MyoD knock-out mice where skeletal muscle is not detected
[42]. These two factors act upstream of MRF4 and myogenin
which are essential for late [43] and terminal myofiber differ-
entiation, respectively [44].
Similarly, quiescent satellite cells characterized by the
expression of Pax7/Myf5 proliferate to become myo-
blasts that also express MyoD. During the process of
myogenic differentiation into mature myofibers, instead,
the expression of Pax7 and Myf5 decreases, levels of
myogenin and MRF4 increase. Finally, MyoD levels
are reduced when mature myoblasts fuse together to
give rise to new myofibers, in which contractile proteins
(like myosin heavy chain, among others) start to be
expressed.
Other thanMRFs, the differential expression of many other
genes controls the activation status of satellite cells: indeed,
the maintenance of quiescence involves more than 500 genes,
mainly responsible for the control of cell-cycle, extra-cellular
matrix formation, and interaction among cells [20]. Cell-cycle
inhibition is determined by Foxo3 and Notch: The Foxo3
transcription factor prevents cell cycle entry and suppresses
terminal differentiation by activating Notch [45], that in turn,
acts as an inhibitor of the p38/MAPK and JNK pathways
necessary for self-renewal [46, 47]. Moreover, the cell-cycle
is arrested by the overexpression of the cyclin-dependent ki-
nases inhibitor p27kip1 and Sprouty1, an inhibitor of MAPK/
ERK pathway [48]. The satellite cell microenvironment holds
satellite cells in quiescence through the interaction of proteins
likeM-cadherin [49] and α7- andβ1-integrins expressed both
on the cell surface and in the niche [50]. The integrity of the
niche itself is also ensured by the expression of
metalloproteinase inhibitors to avoid extracellular matrix deg-
radation [51].
Conversely, upon activation, satellite cells first activate the
p38/MAPK pathway leading toMyf5 andMyoD transcription
factor expression and to subsequent entry in the cell cycle. The
downregulation of Sprouty1 and the increased expression of
TNF alpha, cytokines, and other growth factors released by
the damaged fibers [39, 52, 53] also activate Ekr1/2 and JNK
pathways, while inhibiting the JAK-STAT pathway. The
Wnt4/β-catenin pathway is temporarily activated, but after a
few replicative cycles is downregulated to limit the regenera-
tive process and, together with p21Kip1, p19Arf, and p57
cyclin-dependent kinases, favors differentiation [54–56].
Muscular Dystrophies
Muscular dystrophies are a heterogeneous group of rare
inherited neuromuscular disorders characterized by progres-
sivemuscle weakness andmuscle degeneration. They are clin-
ically, genetically, and biochemically heterogeneous, having
different ages of onset and causing either partial impairment in
mobility or more severe consequences that lead to an early
death [57•]. They derive from mutations in genes coding for
either cytoplasmic, nuclear, membrane, or extracellular matrix
proteins essential for muscle function and homeostasis [58].
Muscular dystrophies are grouped in nine main categories
with multiple subgroups, each defined by a particular pattern
of muscle weakness distribution and clinical severity depen-
dent on the location and type of mutation [57•].
Regardless of the affected protein, multifactorial events
lead to a common outcome for all muscular dystrophies: the
perturbation of the fiber microenviroment by chronic damage
which causes an inflammatory response that exacerbates fiber
degeneration and its replacement by non-functional adipose
and fibrotic scar tissue.
In some muscular dystrophies, the level of the impairment
clinically observed seems to relate to the inability of satellite
cells to effectively contribute to muscle regeneration [59].
Satellite cells become activated to combat the fiber degenera-
tion; however, each cell cycle shortens the telomeres of the
satellite cells and contributes to cell senescence [60, 61], so
that the pool is rapidly exhausted.
Another obstacle to effective muscle regeneration is pre-
sented by the environment in which the regenerative process
takes place: even if a satellite cell itself retains its regenerative
capacity, the dystrophic niche may be hostile and unfavorable
for permitting efficient regeneration [62, 63, 64••].
Moreover, if satellite cells express the mutated gene, regen-
eration may be further impaired from the early stages [65].
One example of this scenario is provided by the severe
Duchenne Muscular Dystrophy (DMD), caused by mutations
in the dystrophin gene located on the X chromosome, where it
spans 2.2 megabases of DNA [66].
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Dystrophin is a membrane-associated protein whose task is
to provide a link between the sarcolemma and cytoplasmic
actin; if absent, myofibers undergo necrosis following repeat-
ed contractions.
Three main kinds of mutations in dystrophin cause DMD:
deletions, duplications, and point mutations [67]. Large intra-
genic deletions and duplications account for about 65 and
10% of cases, respectively, while nonsense mutations and oth-
er small mutations (splice site, small insertions, small dele-
tions, inversions) cover the remaining 25%. Although rear-
rangements can occur anywhere in the dystrophin gene, the
deletions and duplications are located mainly in two hotspots,
the main one being at the 3′ of the gene (exons 44–53) and the
other at the 5′ (exons 3–19).
In satellite cells, there is evidence that dystrophin controls
the determination of their polarity and asymmetric divisions:
the number of muscle progenitors might therefore be de-
creased in DMD, limiting the regenerative lifespan [68] and
contributing to its early exhaustion. Finally, the defective
myoblast differentiation and fusion reported by Delaporte
and Jasmin in 1984 [69, 70] could be considered to impede
the regenerative process.
To date, there are no therapies available to treat muscular
dystrophies. Corticorsteroids are provided as a palliative ther-
apy that can hinder muscle degeneration by interfering with
immune system activation and inflammation arising from
muscle breakdown [71–73]. However, this approach does
not completely stop the disease progression, nor heal the ge-
netic defect, and is associated with considerable long term side
effects.
Genome engineering is a promising alternative strategy,
since by exploiting different nucleases and subsequent path-
ways of DNA repair, it would allow the design of therapies
tailored for each specific mutation causing DMD.
Designing the Path to Precision Medicine: Satellite
Cells Meet CRISPR
The Rise of Genome Engineering Tools
BGenome editing^ or Bgenome engineering^ has recently
emerged as a promising gene therapy approach to allow the
introduction of efficient and precise genetic alterations in a
variety of cells [74]. This technology relies on the use of
programmable nucleases. These are hybrid proteins composed
of domains able to bind DNA in a sequence-specific fashion,
fuse to nonspecific DNA cleavage modules, and can therefore
be addressed to introduce double-strand breaks (DSB) at any
targeted genomic locus. DSBs and the further cell repair
mechanisms that are stimulated to restore the integrity of the
genetic information [75] can be exploited to introduce precise
mutations.
In eukaryotic cells, DSBs are repaired via two distinct path-
ways: homology-directed repair (HDR) and non-homologous
end joining (NHEJ) [76]. HDR pathway occurs only at de-
fined cell cycle stages (during late S phase or G2) and requires
the presence of an identical, or almost identical, sequence to
be used as repair template, while NHEJ involves the simple
ligation of the two DNA ends [77] in an error-prone way that
generates unfaithful repair products derived by the introduc-
tion of small deletions and/or insertions. The two pathways
are responsible for different genomic alterations when applied
to gene editing: HDR is exploited to insert a specific mutation
in the genome or substitute a specific DNA stretch, while
NHEJ can generally be employed to disrupt or, conversely,
restore the reading frame of a mutated gene [74, 78].
Engineered nucleases developed to date include engineered
meganucleases (MNs), zinc finger nucleases (ZFNs), tran-
scription activator-like effector nucleases (TALENs), and
clustered regularly interspaced short palindromic repeats
(CRISPR), each differing in their way of targeting genomic
sequences and mediating double-stranded cleavage [79].
Among them, CRISPR and its associated Cas9 protein has
seen widespread adoption due to its ease of design and low
cost compared to all previous nuclease families, and therefore
it is being widely adopted [74, 80–87].
Three main CRISPR systems, named CRISPR types I, II,
and III, have been identified in bacteria and archaea [88]
where they function as a form of adaptive immunity to defend
themselves against invading phages and plasmids, by using
sequence-specific RNA-guided nucleases that cleave foreign
genetic elements [88, 89].
CRISPR/Cas9 comes from Streptococcus pyogenes and
is a type II CRISPR; the most studied among the three
existing CRISPR systems. Two main components allow
the recognition and cleavage of any genomic region locat-
ed upstream to a –NGG- triplet named Protospacer
Adjacent Motif (PAM): the mature single guide RNA
(sgRNA) and the Cas9 endonuclease. Among the 70 nu-
cleotides that define the sgRNA, the 20 nucleotides located
at its 5′ are involved in the pairing with the target genomic
sequence, while the remaining nucleotides are arranged in
a stem loop able to recruit Cas9 [90] The two Cas9 cata-
lytic sites mediate a blunt double strand-break 3 basepairs
upstream of the genomic PAM sequence. Specifically,
HNH site cleaves the DNA top strand, while the RuvC-
like domains operate the cleavage of the bottom strand
[91]. Depending on the presence or absence of a DNA
template, the cut is re-joined by the intrinsic cell repair
mechanisms HDR or NHEJ, previously mentioned, thus
introducing a permanent genomic alteration. These repair
methods can be selectively exploited depending on the
editing to be performed, potentially extending the applica-
bility of this editing tool to any type of genomic mutation.
This could translate CRISPR-mediated editing into a
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suitable therapeutic approach for the treatment of inherited
diseases caused by a wide mutational spectrum [92].
Engineered Nucleases for Dmd Treatment:
As the most common among the muscular dystrophies,
the design of approaches targeted to DMD has been a
priority in the research field of MDs. Conventional
gene-therapy approaches, focusing on the delivery of
the corrected gene version to the affected cells, have
been attempted in vitro to compensate for the genomic
mutation underlying DMD [93, 94]. However, the ex-
tremely large size of the dystrophin gene limits its pack-
aging into viral vectors, forcing scientists to adopt min-
iaturized dystrophin versions lacking more than 50% of
the protein sequence, which have only partial function-
ality [95–97]. Furthermore, the effect of the exogenous
DNA could be lost over time if non-integrating viral
vectors are chosen for the constructs delivery. On the
contrary, direct sequence-specific alteration of the geno-
mic region could allow the endogenous and permanent
correction of the genetic defect.
In vitro and in vivo cell-therapy-based approaches tested in
DMD patient-derived cells reflected the timeline of the dis-
covery of newer and newer editing tools: MNs, ZFNs,
TALENs, and CRISPR have all been used as proof-of-
concept approaches to demonstrate the suitability of genome
editing to correct DMD myoblasts carrying deletions and out-
of-frame mutations in dystrophin mutational hotspots
[98–100]. The feasibility of the CRISPR approach has also
been demonstrated in induced pluripotent stem cells (iPSC)
derived from DMD patient somatic cells, as myotubes obtain-
ed from iPSC differentiation expressed functional dystrophin
[101]. However, as each of the above-mentioned approaches
aim to target specific mutations, they are only suitable for a
limited patient population. Charles Gersbach therefore intro-
duced the multiplexed CRISPR editing. This used a lentiviral
vector capable of editing multiple sequences at a time, and
was suitable to correct up to 62% of mutations causing
DMD [102].
The ability, described by Partridge in late 80s [6], of
myoblasts derived from a normal donor to restore dys-
trophin expression in the mdx mouse model of DMD,
could be exploited to alleviate the muscle tissue damage
in DMD patients: patients’ myoblasts could in fact be
isolated, corrected in vitro and used for autologous
transplantation, with the advantage that immunosuppres-
sion would not be required and re-administration could
be possible (Fig. 1b).
However, myoblast transplantation for muscular dys-
trophies has limitations: the donor cells mechanism for
homing and engraftment are inefficient, and studies con-
ducted in mice showed that the regenerative response of
transplanted myoblasts is generally low, as the majority
of intra-muscularly transplanted myoblasts die [103].
Also, given the extent of muscle mass and the inacces-
sibility of most of the affected muscles, the heart and
diaphragm included, the choice of the optimal delivery
method is critical.
A better solution to ensure the maintenance of restored
muscle tissue would be targeting the genetics of satellite cells.
The transplantation of freshly isolated satellite cells is more
efficient compared to cultured myoblasts [16, 104], and donor
satellite cells functionally reconstitute the niche [16].
However, this would not be feasible as a treatment, because
it is not possible yet to obtain a sufficient number of freshly
isolated cells for the treatment of all the affected muscles.
Regardless of the chosen target cell type, in vitro genome
engineering might represent a good starting point to evaluate
the specificity of these nucleases through in-depth off-target
analysis, suitable to develop further adjustment and improve-
ment of this technology.
Alternatively, in vivo editing could be exploited to system-
ically deliver the chosen genome editing tool to the affected
tissue. However, this approach could introduce a further issue
related to the immunogenicity that could derive from both the
viral delivery vectors, and the nuclease itself. Since they elicit
a low immune response, adeno-associated viruses have been
recently used by three different groups to mediate in vivo
dystrophin correction in dystrophic mice [105••, 106, 107]
and have proven to be an efficient method for genome editing
tool delivery, even if the rescued dystrophin expression in
satellite cells was quite poor [105••].
Finally, it is important to consider that in vitro and in vivo
therapies will be applied to patients that already manifest a
dystrophic phenotype, but their applicability so far might still
be limited to those in which the damage is not too extensive
for the beneficial effect of edited cells to counteract the degen-
erative process.
A turning point that could allow the body-wide restoration
of the genetic defect is in utero genome editing that would
correct the mutated gene at early developmental stages and
potentially abolish muscle degeneration. Ideally, in the case
of known familial inheritance of such particular genetic disor-
ders, editing of zygotes would be the best solution, since every
cell of the body would carry the restored genetic heritage.
Embryos targeted in later stages could, in fact, generate mo-
saics of corrected and uncorrected cells according to the stage
of nuclease delivery and, as the percent of edited cells would
be variable, only muscles derived from efficiently targeted
cells would express the restored protein. However, it is impor-
tant to consider that, due to the high degree of spontaneous
mutations that can arise, particularly in large genes such as
dystrophin, identification of all at risk pregnancies or indeed
affected embryos generated prior to implantation, would be a
challenging task.
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The Other Side of Engineered Nucleases: Generation
of Muscular Dystrophy Models
Other than for genome correction, engineered nucleases can
be exploited to knock-out or knock-in genes associated with
muscular dystrophy and thus to generate new in vivo and
in vitro models that mimic in the closest possible way the
pathological features are observed in humans. Targeted gene
disruption can be easily obtained bymeans of the NHEJ repair
pathway that follows the double-strand breaks introduced by
the nucleases, while gene knock-in, mediated by the less com-
mon HDR pathway, might be trickier, as the donor DNA has
to be integrated in a precise site.
With regard to Duchenne muscular dystrophy, CRISPR/
Cas9 has been recently used to generate animal models that
complement the repertoire of existing models and better re-
produce the human disease course; The commonly used mdx
mice, in fact, exhibit a much less severe phenotype than pa-
tients [108]. Conversely, CXMD dogs exhibit a more similar
phenotype to the human condition, but their size and longer
lifespan are limiting in terms of research costs [109]. The KO
rat model of Duchenne muscular dystrophy recently devel-
oped by Nakamura [110], who disrupted the dystrophin gene
by designing CRISPR sgRNAs targeted to two dystrophin
exons, has shown a longer disease progression compared to
mdx mice and could therefore better intersect research
requirements.
CRISPR/Cas9 was also used to knock-out dystrophin
in larger mammals that share more genetic and physiolog-
ical similarity with humans compared to rodents: Hong-
Hao Yu obtained 60% of dystrophin targeting by deliver-
ing CRISPR/Cas9 components into pig embryos [111],
from which derived dystrophic pigs characterized by mo-
bility impairment and cardiac involvement, both features
that strictly correlate clinically and functionally to those
observed in patients. Yongchang Chen instead developed
a Rhesus monkey knock-out model in which the CRISPR/
Cas9 targeted 87% of dystrophin alleles [112].
Alternatively, to dramatically reduce the costs of mainte-
nance of these in vivo models, cell lines carrying the desired
mutation could be generated. Fibroblasts obtained from a
healthy donor could be mutated and differentiated towards
the myogenic lineage, as with donor myoblasts, and analyzed
in vitro. However, this technique would require a skin or a
muscle biopsy, which is invasive. Muscle cell lines could be
also obtained from iPSCs, though this may be limited due to
lengthy generation time and outcomes that are dependent on
differences in culturing conditions. Recent works opened the
path to alternative methods to avoid invasive procedures such
as biopsy. Ellis Kim and colleagues found out that a subset of
epithelial cells isolated from urine are inclined to differentiate
into the myogenic lineage and, by using CRISPR/Cas9,
succeeded in the disruption of SGCG gene, mutated in a
particular muscular dystrophy subtype [113]. The source of
this cell type is easily accessible and would ideally allow the
generation of libraries with specific gene mutations.
The generation of disease models with genome editing in-
cludes all the drawbacks that come with its editing properties:
usually both alleles of a gene need to be targeted in order to
obtain the desired change, and off-target effects that might
occur in other genomic regions could interfere with the phe-
notypic outcome.
Editing of the Human Genome: Ethical
Consideration
Genome editing technologies hold future therapeutic potential
for many inherited genetic disorders including the muscular
dystrophies. A promising area of therapeutic development is
somatic cell therapy, which is already in various stages of
clinical trials for a number of disorders.
Due to its wide applicability and ease of customization,
genome engineering has caused unease among many in the
scientific community who have expressed fears that alter-
ations beyond somatic cells may have unknown consequences
for future generations.
Despite widespread uptake of CRISPR-based gene engi-
neering and programmable nucleases in molecular biology,
the technology is still in its infancy. Though progress has been
rapid, off-target effects of the endonucleases are still a concern.
The human genome could potentially contain sequences equal
to or with great similarity to the chosen guide sequence, leading
to unwanted off-target effects that could cause the disruption or
deregulation of other genes, perturbing the individual genetic
heritage. To date, very little evidence exists about the silencing
of nucleases inside cells. Moreover, with respect to the differ-
ential nuclease efficiency in different cells, each clonemay have
a peculiar mosaic distribution of off-target effects.
Heritable genetic engineering is of largest concern to most
regarding the unknown scope of the changes that could be
made; indeed, a moratorium on germline genome editing
was suggested after the results shown in two separate studies
carried out on non-viable human embryos [114, 115]. The
important off-target changes detected in egg, sperm, or em-
bryo DNA, emphasized the fears raised for genome editing
before birth, and opened the path to the moral question of
Bengineered babies^: the possible misuse of genome editing
could lead to the eugenic selection of favorable traits in human
species. Doubts have also been expressed on the use of human
embryos for research, in view of their status of humans.
These issues seem to be overcome if genome editing is meant
to investigate the absolute beginning of human life: scientists
working in UK obtained the approval for the use of CRISPR to
inactivate genes involved in embryo development [116], and
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similarly, several genes have been modified in four-cells healthy
human embryos from Swedish scientists.
Conclusions
Genome editing technologies are quickly developing to overcome
the limitations imposed by classical gene and cell-therapies and
could be adopted as a therapeutic approach for degenerative neu-
romuscular disorders such as muscular dystrophies. Targeting of
the stem cell population responsible for the regeneration ofmuscle
tissue, known as satellite cells, seems a possible way to ensure the
healing of the muscle fiber from an early stage.
To date, none of the classic genome editing tools provides a
suitable solution for the development of effective therapies for
muscular dystrophies, both because muscle tissue is too vast
to be accessed entirely, and because the nuclease delivery and
safety still have to be assessed and optimized.
Genome editing in the zygote would partially limit the issue
related to muscle mass extent and satellite cell accessibility, but
would not help the muscular dystrophies cases arising due to de
novo mutations. The discovery of even more specific editing
nucleases combined with extensive studies on the muscle precur-
sors may help the regenerative medicine field in taking a step
forward to design an effective cure for these devastating disorders.
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